Vaccine Generation of Protective Ebola Antibodies and Identification of Conserved B-Cell Signatures.
J Infect Dis
; 218(suppl_5): S528-S536, 2018 11 22.
Article
em En
| MEDLINE
| ID: mdl-30010811
ABSTRACT
We recently identified a single potently neutralizing monoclonal antibody (mAb), mAb114, isolated from a human survivor of natural Zaire ebolavirus (EBOV) infection, which fully protects nonhuman primates (NHPs) against lethal EBOV challenge. To evaluate the ability of vaccination to generate mAbs such as mAb114, we cloned antibodies from NHPs vaccinated with vectors encoding the EBOV glycoprotein (GP). We identified 14 unique mAbs with potent binding to GP, 4 of which were neutralized and had the functional characteristics of mAb114. These vaccine-induced macaque mAbs share many sequence similarities with mAb114 and use the same mAb114 VH gene (ie, IGHV3-13) when classified using the macaque IMGT database. The antigen-specific VH-gene repertoire present after each immunization indicated that IGHV3-13 mAbs populate an EBOV-specific B-cell repertoire that appears to become more prominent with subsequent boosting. These findings will support structure-based vaccine design aimed at enhanced induction of antibodies such as mAb114.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos B
/
Vacinas contra Ebola
/
Ebolavirus
/
Anticorpos Neutralizantes
/
Anticorpos Monoclonais
/
Anticorpos Antivirais
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article